UAB Neurology Clinic
for
Rett Syndrome
Welcome
to the UAB Civitan-Sparks Clinics Neurology Clinic and Rett
Syndrome Research web site. Here you will find detailed information
about Rett
Syndrome
along with links to research, clinic appointments, and international
online resources related to Rett Syndrome.
The
UAB Neurology Clinic for Rett Syndrome in the UAB
Civitan-Sparks Clinics, a component of the Civitan
International Research Center (CIRC) has been operational
since 1992. The clinic provides comprehensive evaluations
for children with or suspected of having Rett Syndrome.
The
clinic and its research activities are directed by Alan
Percy, M.D., Associate Director of the CIRC. Dr. Percy
is an internationally recognized expert in the diagnosis
and care of children with Rett Syndrome. The clinic has access
to a full range of health professionals available within
the Civitan-Sparks Clinics and The Children’s Hospital
of Alabama. |
 |
Appointments: Clinic appointments are typically
made through referring physicians but inquiries and appointments
can be made by calling Jan Reeves at 205-934-1055 or toll-free
at 1-800-822-2472.
About Rett Syndrome
Rett
Syndrome (RS) is a neurological disorder seen almost exclusively
in females. The prevalence of RS in females is approximately
one in every 10,000-23,000 individuals and is found in all
racial and ethnic
groups worldwide. It is known that RS can occur in males but
is extremely rare. Recurrence in families is also extremely rare.
In these families males may have a very different pattern
including miscarriage, stillbirth or early death due to fatal
encephalopathy.
RS
has its clinical onset in most females between 6-18 months of
age. Development to that time appears normal. This is followed by
a period of stagnation or regression during
which the
child
begins losing
communication skills and
purposeful use of the hands. Afterwards, stereotypical hand movements (such
as hand wringing or knitting motions), gait disturbances, and
a
slowed rate of head growth may be observed.
In
1999 a decade-long search for the genetic basis for RS succeeded
in identifying mutations in the MECP2 gene in girls
fulfilling the criteria for RS. This discovery
allows
confirmation
of clinical diagnoses and
the development of
genotype-phenotype correlations. We are now examining the molecular genetics
of children who do not meet all diagnostic criteria for RS, but who are near
the border zones of clinical involvement. At the present time,
more than 80% of
females fulfilling the criteria for RS have mutations in MECP2. The
remainder either has mutations in as yet unexplored regions of MECP2 or
is explained by alternative genes.
Predicting
the severity of RS for an individual is difficult because more
than 200 mutations in the MECP2 gene have been observed.
The range of these mutations result in varying degrees of neurological
and physical complications and may also lead to
misdiagnosis by health professionals who
may not be familiar with RS. It is most often misdiagnosed as
autism, cerebral palsy or other forms of developmental
delay. Correct diagnosis is essential to receiving quality treatment.
It is strongly suggested to parents that a diagnosis should be
obtained
through a clinical
evaluation using agreed upon clinical criteria and clinical
severity scales.
Most
researchers now agree that RS is a developmental disorder
rather than a progressive, degenerative disorder as once thought.
Survival into adulthood is now expected barring other illnesses
or serious
physical
complications. Girls and women with RS can be expected to demonstrate
a full range of emotions and enjoy satisfying social, recreational,
and educational experiences at home and in the community.
Back to top of page
|